CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint
MT Newswires Live
Yesterday
CSPC Pharmaceutical Group (HKG:1093) SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.
The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.
According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.